This video traces the controversial history of Monsanto's Roundup weed killer, focusing on its active ingredient glyphosate and its alleged links to cancer. It details how Roundup became a global agricultural staple, especially with the introduction of genetically modified "Roundup Ready" crops, leading to a massive increase in its use. The narrative exposes Monsanto's decades-long efforts to suppress scientific findings suggesting glyphosate's carcinogenicity, including lobbying the EPA to alter its conclusions and ghostwriting studies to promote its safety. Following the International Agency for Research on Cancer's 2015 classification of glyphosate as a probable human carcinogen, Monsanto (and its subsequent owner, Bayer) faced a wave of billion-dollar lawsuits. The video highlights Bayer's ongoing strategy to end litigation without adding cancer warnings to Roundup, including extensive lobbying for legal immunity at state and federal levels, drawing parallels to the tobacco industry's tactics.
Roundup's Controversial History: From Agricultural Staple to Health Scandal
0:00 Introduction of Roundup: Monsanto invented Roundup 50 years ago as an effective weed killer.
0:07 Billion-Dollar Health Scandal: Roundup is now at the center of a major health scandal due to links between its active chemical, glyphosate, and various diseases, including cancer (specifically non-Hodgkin's lymphoma).
0:30 Glyphosate's Global Dominance: Thanks to Monsanto, glyphosate became the world's most popular pesticide, now linked to cancer, with accusations of prioritizing shareholder profit over public health.
1:40 The Rise of Roundup Ready Crops: In the 1990s, Monsanto developed genetically modified "Roundup Ready" crops resistant to the herbicide, making Roundup a necessity for farmers and drastically increasing its use from 1.4 million pounds in 1974 to 276 million pounds by 2014.
2:26 Soaring Profits and Safety Claims: This led to skyrocketing profits for Monsanto, with Roundup accounting for half of its sales in 2000. The product was marketed as a "savior" and "safe enough to drink" in comparison to more toxic alternatives like Paraquat.
3:35 Personal Impact - Jim Heuberger: Farmer Jim Heuberger, a long-time Roundup user, was diagnosed with incurable non-Hodgkin's lymphoma in 2022, attributing it to Roundup exposure.
4:14 Decades of Hidden Risks: The cancer risks of glyphosate have allegedly been hidden for decades. An early 1985 EPA study hinted at tumor development in mice, leading the EPA to initially list glyphosate as "possibly carcinogenic to humans."
4:54 Monsanto's Influence on EPA: Monsanto aggressively lobbied the EPA for six years, resulting in the agency capitulating and changing its findings to declare glyphosate non-carcinogenic.
6:01 The IARC Classification (2015): The International Agency for Research on Cancer (IARC) classified glyphosate as a "probable human carcinogen" with specific links to non-Hodgkin lymphoma, directly contradicting the EPA and leading some countries to restrict or ban it.
6:35 Continued EPA Stance & Lawsuits: Despite IARC's ruling, the EPA, influenced by Monsanto's talking points, maintained its stance. However, IARC's announcement triggered a wave of lawsuits against Monsanto for failing to warn consumers.
7:11 Bayer's Acquisition of Monsanto (2018): Monsanto actively sought to sell the company, and Bayer acquired it in 2018. Months later, Bayer settled the first major Roundup lawsuit for $289 million, leading to investor uproar.
7:57 Billions in Settlements & Ongoing Litigation: Bayer has paid over $10 billion in Roundup lawsuits, with approximately 114,000 cases settled and 67,000 cases remaining. Jim Heuberger filed his lawsuit in 2023.
8:58 Bayer's Stance & Avoidance of Warning Labels: Bayer maintains the safety of glyphosate-based products, arguing a cancer warning would be "misleading" and "false," and has resisted adding warning labels despite suggestions from plaintiffs' attorneys as a way to achieve a global settlement.
9:43 Lobbying for Legal Immunity: Bayer has implemented a five-step plan to end lawsuits without warning labels, including lobbying state legislatures for legal immunity. In 2025, bills were introduced in 11 states (successful in Georgia and North Dakota) to protect pesticide companies if they follow EPA labeling, regardless of cancer risks.
10:21 Political Backlash in Iowa: In Iowa, a state representative and palliative care doctor criticized these bills as politically nonsensical amidst a cancer crisis, with polls showing 89% of Iowans opposing such immunity.
11:45 EPA's Continued Position & Corporate Influence: The EPA is updating its evaluation but states that its underlying findings (glyphosate "not likely to be carcinogenic") remain the same, highlighting how the agency considers economic impacts alongside public health.
12:29 Federal Lobbying Efforts: Bayer spent nearly $8.5 million lobbying the federal government in the last year, aiming for federal protections against lawsuits, reportedly with support from the Trump administration.
13:44 Test of Governance: The video concludes by framing the situation as a test of whether government will prioritize corporate profit over public safety and justice for affected individuals.